COCH

Envoy Medical's stock has been impacted by clinical trial milestones, financial results, and corporate news. The company highlighted clinical data presentations and reached milestones in its Acclaim® Cochlear Implant trial. It reported a net loss of $23.8 million for FY 2025, regained compliance with Nasdaq Listing Rule 5550(b)(2), and closed a transformative financing round. The stock has experienced volatility, losing 56.4% over the past year but showing some gains year-to-date.